

# Chirag Dilip Jhaveri MD

Chirag.JhaveriMD@gmail.com or cjhaveri@e-retina.net

## Address:

Retina Consultants of Austin  
3705 Medical Parkway, Ste 410  
Austin, TX 78705

Retina Research Center  
3705 Medical Parkway, Ste 420  
Austin, TX 78705

## Education

### **Vitreoretinal Fellowship: Northwestern University Feinberg School of Medicine**

July 2010 – June 2012

Mentors: Lee M. Jampol, MD; Alice Lyon, MD; Manjot Gill, MD; Rukhsana Mirza, MD; Robert Schroeder, MD

### **Ophthalmology Residency: Louisiana State University/Ochsner – New Orleans, Louisiana**

July 2007 – June 2010

Chief Resident – July 2009 – June 2010

### **Internship: Emory University School of Medicine - Atlanta, Georgia**

July 2006 – June 2007

Class Representative

### **MD Baylor College of Medicine - Houston, Texas**

August 2002 – May 2006

### **B.A. University of Texas at Austin - August 1998 – May 2002**

College of Liberal Arts – Plan II Honors Degree

Graduated with High Honors

## Foreign Languages

Conversational Spanish; Gujarati; Hindi

## Work Experience

### **Retina Consultants of Austin - September 2012 – present**

- Physician

### **Retina Research Center – September 2012 – present**

- Investigator

### **Diabetic Retinopathy Clinical Research Network – January 2016 - present**

- Vice-Chair

### **LSU/Ochsner – Chief Resident – July 2009 - June 2010**

- Involved in preparing site readiness for ACGME visit.
- Planning and organizing wet labs and other educational sessions for residents
- Administrative tasks of managing schedules and vacations for a 24 resident program

### **Baylor College of Medicine – Houston, TX. Jan 2004 – April 2004**

#### *Teaching Assistant – Preclinical Elective Courses*

- Facilitator of weekly group discussions
- Aided and evaluated students in elective coursework

### **UT School of Public Health - Austin, Texas Feb. 2001 – May 2002**

*Chirag Jhaveri*  
2/17/17

#### *Intern/Project Assistant*

- Assisted Dr. Alfred McAlister on Tobacco Settlement Project
- Worked with Dr. Alfred McAlister on Peace Project and developed high school curriculums that stressed non-violence
- Helped in teaching sessions about non-violence at local high schools

#### **Texas Senate Finance Committee** – Austin, Texas Feb. 2001 – May 2001

##### *Legislative Intern*

- Performed research for Bill Hearings and Finance Committee related reports
- Set up Committee member's Bill books for Finance Committee Bill Hearings
- Gained valuable hands-on experience and understanding of legislative processes at the state level

## **Appointments**

#### **Vice-Chair DRCR.net** January 2016-Present

Executive Committee – DRRCR

Operations Group Committee for – DRRCR

#### **Clinical Assistant Professor of Ophthalmology**, Dell Medical School, June 2016-present

Diversity and Inclusion Task Force, Dell Medical School. October 2016-present

#### **Clinical Assistant Professor of Ophthalmology**, Texas A&M University College of Medicine, 2014-present

## **Research Experience**

#### **Vice-Chair DRCR.net** January 2016-Present

On several writing committees.

Member of protocol writing committees for several DRRCR protocols.

#### **Retina Research Center** – Austin, September 2012- Present

PI and Sub-PI on multiple clinical trials.

#### **Northwestern University** – Chicago, 2011

Spectral Domain OCT Imaging of White Spot Syndromes

Presented at Research Day June 2011 Northwestern University

#### **LSU/Ochsner** – New Orleans, 2009

Monofixation syndrome in dense cataracts – evaluating patients with unilateral dense cataracts as a cause of acquired monofixation syndrome

Presented Research Day June 2010 LSU/Ochsner

#### **Baylor College of Medicine** – Houston TX. June 2005

*Research Assistant – Department of Ophthalmology*

- Helped create method of comparing patients with failed PLKs based on several factors.
- Dr. Thomas Harvey, MD – Fellow, Dr. M. Bowes Hamill, M.D. – Faculty

#### **University of Texas at Houston Health Science Center** – May-August 2000

*Laboratory Assistant – Department of Neurosurgery*

- Worked on traumatic brain and spinal cord injury and investigation of liposome delivery into the CNS and PNS
- Performed Immuno-histochemical assays, set up experiments, conducted investigations of motor skills on brain and spinal cord injured rats
- Dr. Raymond J. Grill, PhD and Dr. Guy Clifton, MD – Chair of Neurosurgery

## Clinical Research

- Sub-Investigator: Simultaneous Blockade of Angiopoietin-2 and VEGF-A with the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration (F. Hoffman-La Roche Ltd., CR29521 Stairway)
- Sub-Investigator: A Phase II, Multicenter, Randomized, Active-Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (F. Hoffman-La Roche Ltd, GX28228 Ladder)
- Principal Investigator: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Pilot Study to Evaluate Effects of Emixustat Hydrochloride on Aqueous Humor Biomarkers Associated with Proliferative Diabetic Retinopathy (Acucela Inc., 4439-203)
- Sub-Investigator: A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration (Santen Inc., PAVE study)
- Principal Investigator: A Randomized, Double Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration (Regeneron Pharmaceutical, Inc, R910-3-AMD-1517 ONYX)
- Principal Investigator: A Multiple-Center, Multiple-Doses, Randomized, Active Comparator-Controlled, Double-Masked, Parallel-Group, 28-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Diabetic Macular Edema (Genentech BP30099 Boulevard)
- Principal Investigator: Intravitreal Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk (DRCR Protocol W)
- Sub-Investigator: Genes in Diabetic Retinopathy Project (DRCR Genetics)
- Sub-Investigator: Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (DRCR Protocol S)
- Sub-Investigator: A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Genentech BP29647 Avenue)
- Sub-Investigator: A Phase 2 Multicenter, Randomized, Controlled, Double-Masked Clinical Trial Designed to Evaluate the Safety and Exploratory efficacy of Luminate® (ALG-1001) as Compared to Avastin® in the Treatment of Diabetic Macular Edema (Allegro Ophthalmics, LLC, DME 202B)
- Sub-Investigator: An open-label single ascending dose and randomized double-masked, ranibizumab controlled, safety, tolerability, and efficacy study of intravitreal LMG324 in subjects with neovascular age-related macular degeneration (Alcon Research, LTD, LMG324-2201)
- Sub-Investigator: A randomized, multi-center, single masked, sham controlled, proof-of-concept study of intravitreal CLG561 as a monotherapy and in combination with LFG316 in subjects with geographic atrophy (Alcon Research, LTD, CLG561-2201)
- Sub-Investigator: A Phase 4 Safety Study of IOP Signals in Patients Treated with Iluvien® (Fluocinolone Acetonide Intravitreal Implant) 0.19 MG (Alimera Sciences, Inc., M-01-15-004)

- Sub-Investigator: Prospective, Multicenter Post-Approval Study (PAS) of Visioncare's Implantable Miniature Telescope (By Dr. Isaac Lipshitz) in Patients with Bilateral Severe to Profound Central Vision Impairment Associated with End-Stage Age-Related Macular Degeneration (VisionCare Ophthalmic Technologies, IMT-PAS-01)
- Sub-Investigator: Clinical Study Protocol Phase I Dose Escalation and Expansion Study of DS-7080a in Subjects with Neovascular Age-Related Macular Degeneration (Daichi Sankyo Pharma Development, DS7080-A-U101)
- Principal Investigator: A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects with Neovascular Age-Related Macular Degeneration (Alcon Research, Ltd., RTH258-E003)
- Principal Investigator: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients with Geographic Atrophy (GA) - FILLY – (Apellis Pharmaceuticals, Inc., POT-CP121614)
- Principal Investigator: A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority Study of X-82 plus *prn* Eylea® Compared to *prn* Eylea® Monotherapy in Neovascular AMD (Tyrogenex, Inc., X82-OPH-201)
- Sub-Investigator: A Phase II Proof-of-Concept Study of the Safety and Efficacy of HuCNS-SC Subretinal Transplantation in Subjects with Geographic Atrophy of Age-Related Macular Degeneration (StemCells, Inc., CL-AMD-201)
- Principal Investigator: Prospective, observational longitudinal study addressing Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time (DRCR AA)
- Sub-Investigator: A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration (Alcon Research Ltd. RTH258-C001)
- Sub-Investigator: A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration (Iconic Therapeutics IT-002)
- Sub-Investigator: A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema (Astellas Pharma Europe B.V. VIDI)
- Principal Investigator: A randomized, parallel group, double-masked, active-controlled Phase 1/2 clinical Trial to evaluate the efficacy and safety of dexamethasone sodium phosphate Visulex system for the treatment of non-infectious anterior uveitis (Aciont, Inc. DSPV-201)
- Sub-Investigator: A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patient with Geographic Atrophy Secondary to Age-Related Macular Degeneration (Genentech GX29176 Chroma)
- Sub-Investigator: Study of Comparative Treatments for Retinal Vein Occlusion 2 [SCORE2]: A Multicenter, Prospective, Randomized Non-Inferiority Trial of Eyes with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 weeks with Intravitreal Aflibercept Every 4 weeks (SCORE2)
- Sub-Investigator: A Randomized, Double Masked, Placebo Controlled Study Evaluating ORACEA® in Subjects with Geographic Atrophy Secondary to Non-Exudative

Age-Related Macular Degeneration (University of Virginia Department of Ophthalmology TOGA)

- Sub-Investigator: A Phase 1 Open-Label, Multi-Center Trial with Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration (AMD) (Panoptica PAN-90806)
- Sub-Investigator: A Phase 2, Randomized, Active- Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects with Diabetic Macular Edema (Aerpio AKB-9778):
- Principal Investigator: Ocriplasmin Research to Better Inform Treatment (Thrombogenics TG-MV-018 ORBIT)
- Principal Investigator: Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity (DRCR Protocol V)
- Sub-Investigator: Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy in Pseudophakic Eyes (DRCR Protocol U)
- Sub-Investigator: A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X 0.024% (Latanoprostene Bunod) Ophthalmic Solution with Timolol Maleate Ophthalmic Solution 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension (Bausch & Lomb APOLLO)
- Sub-Investigator: A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of Fovista (Anti PDG-F Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration (Ophthotech Corp. OPH1003)
- Sub-Investigator: A prospective, Two Cohort, Single-Masked, Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects with Exudative Age-Related Macular Degeneration (Alcon C-13-001 ESBA1008)
- Sub-Investigator: An Open-Label, Non-randomized, Single-Arm, Roll-Over Study to Continue Dosing of Gevokizumab in Non-Infectious Intermediate, Posterior, or Pan- Uveitis Patients Who Each Successfully Completed either the X052130 or the X052131 Study (XOMA X052132)
- Sub-Investigator: A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina in Adults Patients with Diabetic Macular Edema (Ampio Pharmaceuticals, Optina Danazol Oral Capsule Clinical Study AP-05-002)
- Sub-Investigator: A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel Group, Multi Center, Study to Compare the Efficacy and Safety of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) with that of Ranibizumab in Adult Subjects with Diabetic Macular Edema (Pfizer PF-04634817)
- Sub-Investigator: A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema (DRCR Protocol T)
- Sub-Investigator: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan-Uveitis (XOMA X052130)
- Sub-Investigator: A Randomized, Double-Masked, Placebo-Controlled Study of the Safety and

Efficacy of Gevokizumab in the Treatment of Subjects with Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled with Systemic Treatment (XOMA X052131)

Sub-Investigator: A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema with Involvement of the FoveAL Center (Juvenile Diabetes Research Foundation International iDEAL Study)

Sub-Investigator: An Open-label Dose Escalation Study of PF-04523655 (Stratum I) Combined With a Prespective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating the Efficacy and Safety of PF-04523655 Alone and in Combination with Ranibizumab Versus Ranibizumab Alone in Diabetic Macular Edema (Quark, MATISSE Study)

Sub-Investigator: Effect of Diabetes Education during Retinal Ophthalmology Visits on Diabetes Control (DRCR M)

## Publications

Chexal S, Gunderson I, BS, Berger BB, Jhaveri C. A Novel Retina Today, May/June 2016 72-78.

Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. *Ophthalmology*. 2016 Jun;123(6):1351-9. doi: 10.1016/j.optha.2016.02.022.

Aiello LP, Ayala AR, Antoszyk AN, Arnold-Bush B, Baker C, Bressler NM, Elman MJ, Glassman AR, Jampol LM, Melia M, Nielsen J, Wolpert HA; Diabetic Retinopathy Clinical Research Network. Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial. *JAMA Ophthalmol*. 2015 Aug;133(8):888-96. doi: 10.1001/jamaophthalmol.2015.1312

Bressler SB, Almkhater T, Bhorade A, Bressler NM, Glassman AR, Huang SS, Jampol LM, Kim JE, Melia M; Diabetic Retinopathy Clinical Research Network Investigators. Repeated intravitreal ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. *JAMA Ophthalmol*. 2015 May;133(5):589-97. doi: 10.1001/jamaophthalmol.2015.186

Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med*. 2015 Mar 26;372(13):1193-203. doi: 10.1056/NEJMoa1414264. Epub 2015 Feb 18

Danylkova N, Gupta N, Jhaveri CD, Gill MK. Suprachoroidal silicone oil migration following retinal detachment repair. *Ophthalmic Surg Lasers Imaging Retina*. 2013 May-Jun;44(3):284-6. doi: 10.3928/23258160-20130503-14

Jhaveri CD, Jampol LM, Van Gelder RN, Cunningham ET Jr. Diagnostic and therapeutic challenges. *Retina*. 2012 May;32(5):1028-32. doi: 10.1097/IAE.0b013e3182437e54.

## Scientific Posters

**The Effect of Brolicizumab Applied by Microvolume Injection or Infusion in Patients With Neovascular Age-Related Macular Degeneration. Association for Research in Vision and Ophthalmology Annual Meeting, Seattle, WA May 2016.**